Detalhe da pesquisa
1.
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
Circulation
; 141(20): 1600-1607, 2020 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32223429
2.
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.
Circulation
; 141(8): 616-623, 2020 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707849
3.
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjectsã- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial.
Circ J
; 85(11): 2063-2070, 2021 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33980763
4.
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
Circulation
; 139(12): 1483-1492, 2019 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30586750
5.
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
Stroke
; 51(5): 1546-1554, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32312223
6.
Cognitive Function in a Randomized Trial of Evolocumab.
N Engl J Med
; 377(7): 633-643, 2017 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-28813214
7.
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
N Engl J Med
; 376(18): 1713-1722, 2017 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28304224
8.
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Circulation
; 137(4): 338-350, 2018 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29133605
9.
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
Circulation
; 138(8): 756-766, 2018 08 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29626068
10.
Inflammatory and Cholesterol Risk in the FOURIER Trial.
Circulation
; 138(2): 131-140, 2018 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29530884
11.
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
Lancet
; 392(10155): 1311-1320, 2018 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30293769
12.
BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study.
Am Heart J
; 208: 37-46, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30530121
13.
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Lancet
; 390(10106): 1962-1971, 2017 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28859947
14.
The Success Story of LDL Cholesterol Lowering.
Circ Res
; 118(4): 721-31, 2016 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26892969
15.
Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS).
Circulation
; 134(6): 455-68, 2016 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27486164
16.
Darapladib for preventing ischemic events in stable coronary heart disease.
N Engl J Med
; 370(18): 1702-11, 2014 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24678955
17.
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.
Am Heart J
; 173: 94-101, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26920601
18.
Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.
Ophthalmology
; 123(1): 51-9, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26477842
19.
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
Eur Heart J
; 41(1): 111-188, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31504418
20.
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.
Eur Heart J
; 36(24): 1536-46, 2015 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25802390